Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fuchs

Showing results (571-580 of 917) with videos related to

Pageof 92
Sort By:
Nuklearmedizin. Nuclear Medicine|December 1, 1996
[Impairment of myocardial perfusion reserve in microvascular angina (syndrome X): assessment by 99mTc-MIBI-SPECT]K Langes, B Beuthien-Baumann, M Lübeck, et al.
The Journal of Antimicrobial Chemotherapy|January 1, 1989
Desacetylcefotaxime--another broad spectrum cephalosporin?P C Fuchs, R N Jones, A L Barry, et al.
American Journal of Clinical Pathology|December 1, 1978
Reassessment of the "class" concept of disk susceptibility testing. Cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporinsA L Barry, C Thornsberry, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 1995
Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters, to two fluoroquinolones (grepafloxacin and PD 131628)D L Sewell, A L Barry, S D Allen, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1977
Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolatesR N Jones, P C Fuchs, T L Gavan, et al.
The American Journal of the Medical Sciences|November 1, 1977
Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolatesP C Fuchs, T L Gavan, E H Gerlach, et al.
Neuropharmacology|June 16, 2007
Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptorsJakob von Engelhardt, Irinel Coserea, Verena Pawlak, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1989
Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strainsR N Jones, M A Pfaller, P C Fuchs, et al.
Journal of Clinical Microbiology|January 1, 1987
Quality control limits for microdilution susceptibility tests with norfloxacinA L Barry, T L Gavan, L W Ayers, et al.
Photobiomodulation, Photomedicine, and Laser Surgery|May 10, 2024
High-Intensity Blue Light (450-460 nm) Phototherapy for <i>Pseudomonas aeruginosa</i>-Infected WoundsAndreas Zoric, Mahsa Bagheri, Maria von Kohout, et al.
Pageof 92

Showing results (571-580 of 917) with videos related to

Sort By:
Pageof 92
Nuklearmedizin. Nuclear Medicine|December 1, 1996
[Impairment of myocardial perfusion reserve in microvascular angina (syndrome X): assessment by 99mTc-MIBI-SPECT]K Langes, B Beuthien-Baumann, M Lübeck, et al.
The Journal of Antimicrobial Chemotherapy|January 1, 1989
Desacetylcefotaxime--another broad spectrum cephalosporin?P C Fuchs, R N Jones, A L Barry, et al.
American Journal of Clinical Pathology|December 1, 1978
Reassessment of the "class" concept of disk susceptibility testing. Cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporinsA L Barry, C Thornsberry, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 1995
Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters, to two fluoroquinolones (grepafloxacin and PD 131628)D L Sewell, A L Barry, S D Allen, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1977
Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolatesR N Jones, P C Fuchs, T L Gavan, et al.
The American Journal of the Medical Sciences|November 1, 1977
Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolatesP C Fuchs, T L Gavan, E H Gerlach, et al.
Neuropharmacology|June 16, 2007
Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptorsJakob von Engelhardt, Irinel Coserea, Verena Pawlak, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1989
Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strainsR N Jones, M A Pfaller, P C Fuchs, et al.
Journal of Clinical Microbiology|January 1, 1987
Quality control limits for microdilution susceptibility tests with norfloxacinA L Barry, T L Gavan, L W Ayers, et al.
Photobiomodulation, Photomedicine, and Laser Surgery|May 10, 2024
High-Intensity Blue Light (450-460 nm) Phototherapy for <i>Pseudomonas aeruginosa</i>-Infected WoundsAndreas Zoric, Mahsa Bagheri, Maria von Kohout, et al.
Pageof 92